Tergene Biotech, an Indian start up, has developed a promising vaccine candidate to combat pneumonia. The vaccine is targeted against specific types of bacteria that cause pneumonia in India, South Asia and Africa.
Founded by Mr M Kuppusamy, a biotechnologist and veteran in the vaccine industry, Tergene is deploying novel vaccine technology to cut time and cost and make the vaccine affordable. Current vaccines are priced at Rs 3,500 per dose and the immunization program involves three doses. This makes the vaccine highly inaccessible to low income groups.
Earlier in 2015, one of India's drugmaker Aurobindo Pharma had announced a joint venture with Tergene to create the pneumonia vaccine candidate. Aurobindo will have a majority stake in the JV and will fund the product development in a phased manner spanning over three years.